Items where Author is "Naci, Huseyin"

Number of items: 125.
  • Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe:lessons for the accelerated approval pathway. (2024) Shahzad, Mahnum; Naci, Huseyin; Esselen, Katharine M.; Dottino, Joseph A.; Wagner, Anita K. picture_as_pdf
  • Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England:a retrospective evidence-based analysis. (2024) Lythgoe, Mark P.; Emhardt, Alica Joana; Naci, Huseyin; Krell, Jonathan; Sullivan, Richard; Aggarwal, Ajay picture_as_pdf
  • Intended and unintended outcomes after FDA pediatric antidepressant warnings:a systematic review. (2024) Soumerai, Stephen B.; Koppel, Ross; Naci, Huseyin; Madden, Jeanne M.; Fry, Andra; Halbisen, Alyssa; Angeles, Jesenia; Koppel, Jonah; Rubin, Rachelle; Lu, Christine Y. picture_as_pdf
  • Treatment effects in randomized and nonrandomized studies of pharmacological interventions:a meta-analysis. (2024) Salcher-Konrad, Maximilian; Nguyen, Mary; Savović, Jelena; Higgins, Julian P. T.; Naci, Huseyin picture_as_pdf
  • Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data:a retrospective analysis. (2024) Naci, Huseyin; Zhang, Yichen; Woloshin, Steven; Guan, Xiaodong; Xu, Ziyue; Wagner, Anita K. picture_as_pdf
  • Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. (2023) Zhou, Yue; Naci, Huseyin; Chen, Dingyi; Bai, Lin; Shi, Luwen; Guan, Xiaodong; Wagner, Anita Katharina picture_as_pdf
  • Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil:a retrospective analysis. (2023) Ivama-Brummell, Adriana M.; Marciniuk, Fernanda L; Wagner, Anita K.; Osorio-de-Castro, Claudia G. S.; Vogler, Sabine; Mossialos, Elias; Tavares-de-Andrade, Carla L.; Naci, Huseyin picture_as_pdf
  • Communication of anticancer drug benefits and related uncertainties to patients and clinicians:document analysis of regulated information on prescription drugs in Europe. (2023) Davis, Courtney; Wagner, Anita K.; Salcher-Konrad, Maximilian; Scowcroft, Henry; Mintzes, Barbara; Pokorny, Adrian M J; Lew, Jianhui; Naci, Huseyin picture_as_pdf
  • Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. (2023) Shahzad, Mahnum; Naci, Huseyin; Wagner, Anita K.
  • Characteristics of prior authorization policies for new drugs in Medicare Part D. (2023) Naci, Huseyin; Forrest, Robin; Zhai, Mike; Stofesky, Amanda R.; Kesselheim, Aaron S. picture_as_pdf
  • Vitruvian plot:a visualisation tool for multiple outcomes in network meta-analysis. (2022) Ostinelli, Edoardo Giuseppe; Efthimiou, Orestis; Naci, Huseyin; Furukawa, Toshi A.; Leucht, Stefan; Salanti, Georgia; Wainwright, Laurence; Zangani, Caroline; De Crescenzo, Franco; Smith, Katharine; Stevens, Katherine; Liu, Qiang; Cipriani, Andrea picture_as_pdf
  • Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland. (2022) Carl, David L.; Laube, Yannic; Serra-Burriel, Miquel; Naci, Huseyin; Ludwig, Wolf Dieter; Vokinger, Kerstin N. picture_as_pdf
  • Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. (2022) Cherla, Avi; Mossialos, Elias; Salcher-Konrad, Maximilian; Kesselheim, Aaron S.; Naci, Huseyin picture_as_pdf
  • Overall survival benefits of cancer drugs approved in China from 2005 to 2020. (2022) Zhang, Yichen; Naci, Huseyin; Wagner, Anita K.; Xu, Ziyue; Yang, Yu; Zhu, Jun; Ji, Jiafu; Shi, Luwen; Guan, Xiaodong picture_as_pdf
  • Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer:a systematic review and network meta-analysis. (2022) Athanasiou, Antonios; Veroniki, Areti Angeliki; Efthimiou, Orestis; Kalliala, Ilkka; Naci, Huseyin; Bowden, Sarah; Paraskevaidi, Maria; Arbyn, Marc; Lyons, Deirdre; Martin-Hirsch, Pierre; Bennett, Phillip; Paraskevaidis, Evangelos; Salanti, Georgia; Kyrgiou, Maria picture_as_pdf
  • Pharmacy interventions on COVID-19 in Europe:mapping current practices and a scoping review. (2022) Costa, Suzete; Romão, Mariana; Mendes, Maria; Horta, Maria Rute; Rodrigues, António Teixeira; Carneiro, António Vaz; Martins, Ana Paula; Mallarini, Erika; Naci, Huseyin; Babar, Zaheer Ud Din picture_as_pdf
  • Coverage of new drugs in Medicare Part D. (2022) Naci, Huseyin; Kyriopoulos, Ilias-Ioannis; Feldman, William B.; Hwang, Thomas J.; Kesselheim, Aaron S.; Chandra, Amitabh picture_as_pdf
  • Study design, result posting, and publication of late-stage cardiovascular trials. (2022) Kapelios, Chris J.; Naci, Huseyin; Vardas, Panos E.; Mossialos, Elias
  • Price changes and within-class competition of cancer drugs in the USA and Europe:a comparative analysis. (2022) Vokinger, Kerstin N.; Hwang, Thomas J.; Carl, David L.; Laube, Yannic; Ludwig, Wolf Dieter; Naci, Huseyin; Kesselheim, Aaron S.
  • Ethical implications of poor comparative effectiveness evidence:obligations in industry-research partnerships. (2020) Singh, Ilina; Naci, Huseyin; Miller, Jennifer; Caplan, Arthur; Cipriani, Andrea picture_as_pdf
  • Generating comparative evidence on new drugs and devices after approval. (2020) Cipriani, Andrea; Ioannidis, John P.A.; Rothwell, Peter M.; Glasziou, Paul; Li, Tianjing; Hernandez, Adrian F.; Tomlinson, Anneka; Simes, John; Naci, Huseyin picture_as_pdf
  • Generating comparative evidence on new drugs and devices before approval. (2020) Naci, Huseyin; Salcher-Konrad, Maximilian; Kesselheim, Aaron S.; Dr.rer.nat, Beate Wiesler; Rochaix, Lise; Redberg, Rita; Salanti, Georgia; Jackson, Emily; Garner, Sarah; Stroup, Scott; Cipriani, Andrea picture_as_pdf
  • Association between the use of surrogate measures in pivotal trials and health technology assessment decisions:a retrospective analysis of NICE and CADTH reviews of cancer drugs. (2020) Pinto, Ashlyn; Naci, Huseyin; Neez, Emilie; Mossialos, Elias picture_as_pdf
  • Prognostic significance of left ventricular noncompaction:systematic review and meta-analysis of observational studies. (2020) Aung, Nay; Doimo, Sara; Ricci, Fabrizio; Sanghvi, Mihir M.; Pedrosa, Cesar; Woodbridge, Simon P.; Al-Balah, Amer; Zemrak, Filip; Khanji, Mohammed Y.; Munroe, Patricia B.; Naci, Huseyin; Petersen, Steffen E. picture_as_pdf
  • European Medicines Agency’s Priority Medicines scheme at 2 years:an evaluation of clinical studies supporting eligible drugs. (2019) Neez, Emilie Marie Celine Anne; Hwang, Thomas; Sahoo, Samali Anova; Naci, Huseyin picture_as_pdf
  • Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16:cross-sectional analysis. (2019) Naci, Huseyin; Davis, Courtney; Savović, Jelena; Higgins, Julian P. T.; Sterne, Jonathan; Gyawali, Bishal; Romo Sandoval, Xochitl Citlalli; Handley, Nicola; Booth, Christopher M picture_as_pdf
  • Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer:protocol for a systematic review and network meta-analysis from the CIRCLE Group. (2019) Athanasiou, Antonios; Veroniki, Areti Angeliki; Efthimiou, Orestis; Kalliala, Ilkka; Naci, Huseyin; Bowden, Sarah; Paraskevaidi, Maria; Martin-Hirsch, Pierre; Bennett, Philip; Paraskevaidis, Evangelos; Salanti, Georgia; Kyrgiou, Maria picture_as_pdf
  • Combining multiple treatment comparisons with personalized patient preferences:a randomized trial of an interactive platform for statin treatment selection. (2019) Hopkin, Gareth; Au, Anson; Collier, Verena Jane; Yudkin, John S; Basu, Sanjay; Naci, Huseyin picture_as_pdf
  • Personalizing second-line Type 2 diabetes treatment selection:combining network meta-analysis, individualized risk, and patient preferences for unified decision support. (2019) Choi, Sung Eun; Berkowitz, Seth A.; Yudkin, John S.; Naci, Huseyin; Basu, Sanjay
  • Impact of predictive medicine on therapeutic decision making:a randomized controlled trial in congenital heart disease. (2019) Naci, Huseyin; Salcher-Konrad, Maximilian; Mcguire, Alistair; Berger, Felix; Kuehne, Titus; Goubergrits, Leonid; Muthurangu, Vivek; Wilson, Ben; Kelm, Marcus picture_as_pdf
  • New agreement on branded drugs for the NHS. (2019) Naci, Huseyin; Dixon, Jennifer
  • Assessment of devices, diagnostics and digital technologies: a review of NICE medical technologies guidance. (2018) Crispi, Francisca; Naci, Huseyin; Barkauskaite, Eva; Osipenko, Leeza; Mossialos, Elias picture_as_pdf
  • The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. (2018) Wallach, Joshua D.; Ross, Joseph S.; Naci, Huseyin
  • The US Food and Drug Administration’s expedited approval programs: addressing premarket flexibility with enhanced postmarket evidence generation. (2018) Wallach, Joshua D.; Ross, Joseph S.; Naci, Huseyin
  • Training the next generation of cardiovascular leaders in health policy and economics. (2017) Naci, Huseyin; Vardas, Panos; Vahanian, Alec; Kirchhof, Paulus; Bardinet, Isabel; Mossialos, Elias
  • Accelerated access to new drugs and technologies. (2017) Naci, Huseyin; Mossialos, Elias
  • What to do (or not to do) when randomization is not possible. (2017) Naci, Huseyin
  • Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. (2017) Davis, Courtney; Naci, Huseyin; Gurpinar, Evrim; Poplavska, Elita; Pinto, Ashlyn; Aggarwal, Ajay
  • Health policy in times of austerity — a conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. (2017) Wenzl, Martin; Naci, Huseyin; Mossialos, Elias
  • Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. (2017) Naci, Huseyin; Smalley, Katelyn R.; Kesselheim, Aaron S.
  • Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. (2017) Naci, Huseyin; Wouters, Olivier J.; Gupta, Radhika; Ioannidis, John P. A.
  • The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. (2017) Kaier, K.; Reinecke, H.; Naci, Huseyin; Frankenstein, L.; Bode, M.; Vach, W.; Hehn, P.; Zirlik, A.; Zehender, M.; Reinöhl, J.
  • Communication of treatment rankings obtained from network meta-­analysis using data visualization. (2016) Naci, Huseyin
  • What works best in congenital heart disease? Comparing two interventions for treatment of Aortic Coarctation. (2016) Olczak, Kaya; Salcher, Maximillian; Naci, Huseyin
  • Cost implications of using different ECG criteria for screening young athletes in the United Kingdom. (2016) Dhutia, Harshil; Malhotra, Aneil; Gabus, Vincent; Merghani, Ahmed; Finocchiaro, Gherardo; Millar, Lynne; Narain, Rajay; Papadakis, Michael; Naci, Huseyin; Tome, Maite; Sharma, Sanjay
  • History bias, study design, and the unfulfilled promise of pay-for-performance policies in health care. (2016) Naci, Huseyin; Soumerai, Stephen B.
  • Balloon dilatation and stenting for aortic coarctation: a systematic review and meta-analysis. (2016) Salcher, Maximilian; Naci, Huseyin; Law, Tyler J.; Kuehne, Titus; Schubert, Stephan; Kelm, Marcus
  • Economic evaluation of mental health interventions: an introduction to cost-utility analysis. (2016) Luyten, Jeroen; Naci, Huseyin; Knapp, Martin
  • QALYs in cost-effectiveness analysis: an overview for cardiologists. (2015) Wouters, Olivier J.; Naci, Huseyin; Samani, Nilesh J
  • Preventing cardiovascular events with empagliflozin: at what cost? (2015) Naci, Huseyin; Basu, Sanjay; Yudkin, John S
  • Why the drug development pipeline is not delivering better medicines. (2015) Naci, Huseyin; Carter, Alexander W.; Mossialos, Elias
  • Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. (2015) Tervonen, Tommi; Naci, Huseyin; van Valkenhoef, Gert; Ades, Anthony E.; Angelis, Aris; Hillege, Hans L.; Postmus, Douwe
  • Double failure: the shared accountability of governments and firms for the innovation deficit in the pharmaceutical sector. (2015) Naci, Huseyin; Carter, Alexander W.; Mossialos, Elias picture_as_pdf
  • Evaluation of wellness determinants and interventions by citizen scientists. (2015) Naci, Huseyin; Ioannidis, John P. A.
  • From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. (2015) Mossialos, Elias; Courtin, Emilie; Naci, Huseyin; Benrimoj, Shalom; Bouvy, Marcel; Farris, Karen; Noyce, Peter; Sketris, Ingrid picture_as_pdf
  • How good is "Evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of clinical utility of drugs. (2015) Naci, Huseyin; Ioannidis, John P. A.
  • National approaches to comparative effectiveness research. (2015) Naci, Huseyin; Spackman, Eldon; Fleurence, Rachael
  • Rethinking the appraisal and approval of drugs for type 2 diabetes. (2015) Naci, Huseyin; Lehman, Richard; Wouters, Olivier J.; Goldacre, Ben; Yudkin, John S
  • Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. (2015) Naci, Huseyin; Cooper, Jacob; Mossialos, Elias
  • An assessment of the methodological quality of published network meta-analyses: a systematic review. (2015) Chambers, James D.; Naci, Huseyin; Wouters, Olivier J.; Pyo, Junhee; Gunjal, Shalak; Kennedy, Ian R.; Hoey, Mark G.; Winn, Aaron; Neumann, Peter J.
  • Does industry sponsorship bias research findings? (2014) Naci, Huseyin
  • Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. (2014) Naci, Huseyin; Dias, Sofia; Ades, A. E.
  • Regulators should better leverage effectiveness standards to enhance drug value. (2014) Naci, Huseyin; Alexander, George Caleb
  • Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. (2014) Naci, Huseyin; van Valkenhoef, G.; Higgins, J. P. T.; Fleurence, R.; Ades, A. E.
  • Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions. (2014) Naci, Huseyin; Soumerai, Stephen B; Ross-Degnan, Dennis; Zhang, Fang; Briesacher, Becky A.; Gurwitz, Jerry H.; Madden, Jeanne M. picture_as_pdf
  • Persistent medication affordability problems among disabled medicare beneficiaries after Part D, 2006-2011. (2014) Naci, Huseyin
  • Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. (2013) Naci, Huseyin; O’Connor, Alec B
  • Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. (2013) Naci, Huseyin; Brugts, Jasper Jan; Fleurence, Rachael; Ades, Anthony E.
  • Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. (2013) Naci, Huseyin; Brugts, Jasper Jan; Ades, Tony
  • Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. (2013) Jansen, Jeroen P.; Naci, Huseyin
  • Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence? (2013) Mossialos, Elias; Naci, Huseyin; Courtin, Emilie
  • Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. (2013) Naci, Huseyin; Brugts, Jasper Jan; Fleurence, Rachael; Ades, Anthony E.
  • Improving health care services in Northern Cyprus: a call for research and action. (2012) Rahmioglu, Nilufer; Naci, Huseyin; Cylus, Jonathan
  • The economics of health care delivery. (2012) Winter, H.S.; Mossialos, E.; Naci, Huseyin; Chandra, A.; Salojee, H.; Yamashiro, Y.; Bhutta, Z.A.; Uauy, R.; Corvalan, C.
  • Why a stricter regulation of drugs could foster (not deter) pharmaceutical innovation. (2012) Naci, Huseyin; Cylus, Jonathan
  • Raising the bar for market authorisation of new drugs. (2012) Naci, Huseyin; Cylus, Jonathan; Vandoros, Sotiris; Sato, Azusa; Perampaladas, Kumar
  • Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. (2012) Naci, Huseyin; de Lissovoy, Gregory; Hollenbeak, Christopher; Custer, Brian; Hofmann, Axel; McClellan, William; Gitlin, Matthew
  • Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study. (2012) Chisholm, Daniel; Naci, Huseyin; Hyder, Adnan Ali; Tran, Nhan T.; Peden, Margie
  • Using indirect evidence to determine the comparative effectiveness of prescription drugs: do benefits outweigh risks? (2011) Naci, Huseyin; Fleurence, Rachael
  • Evidence of comparative efficacy should have a formal role in European drug approvals. (2011) Sorenson, Corinna; Naci, Huseyin; Cylus, Jonathan; Mossialos, Elias
  • The increasing need to harmonize evidence demands of regulators, payers, and health technology assessment bodies in Europe – opportunities and challenges. (2011) Naci, Huseyin
  • The critical role of observational evidence in comparative effectiveness research. (2010) Fleurence, Rachel L.; Naci, Huseyin; Jansen, Jeroen P.
  • Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. (2010) McIntyre, Roger S.; Cragin, Lael; Sorensen, Sonja; Naci, Huseyin; Baker, Tim; Roussy, Jean-Pascal
  • Economic burden of multiple sclerosis. (2010) Naci, Huseyin; Fleurence, Rachael; Birt, Julie; Duhig, Amy
  • The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. (2010) Naci, Huseyin; Fleurence, Rachael; Birt, Julie; Duhig, Amy
  • Productivity losses from road traffic deaths in Turkey. (2008) Naci, Huseyin; Baker, Timothy D.
  • One island, two parts, shared aspirations. (2007) Naci, Huseyin; Leontsini, Elli; Baker, Timothy D.
  • Approval of cancer drugs with uncertain therapeutic value:a comparison of regulatory decisions in Europe and the United States. Salcher-Konrad, Maximilian; Naci, Huseyin; Davis, Courtney picture_as_pdf
  • Assessment of coverage in England of cancer drugs qualifying for US food and drug administration accelerated approval. Cherla, Avi; Naci, Huseyin; Kesselheim, Aaron S.; Gyawali, Bishal; Mossialos, Elias picture_as_pdf
  • Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies. Wouters, Olivier J.; Naci, Huseyin; Papanicolas, Irene picture_as_pdf
  • Availability of new medicines in the US and Germany from 2004 to 2018. Blankart, Katharina; Naci, Huseyin; Chandra, Amitabh picture_as_pdf
  • Can social norms promote sustainable food consumption? A systematic review. Pollicino, Daniele; Zamzow, Heidi; Shreedhar, Ganga; Galizzi, Matteo M.; Naci, Huseyin; Freitag, Patricia picture_as_pdf
  • Cancer drug indication approvals in China and the United States:a comparison of approval times and clinical benefit, 2001–2020. Wei, Yuxuan; Zhang, Yichen; Xu, Ziyue; Wang, Guoan; Zhou, Yue; Li, Huangqianyu; Shi, Luwen; Naci, Huseyin; Wagner, Anita K.; Guan, Xiaodong picture_as_pdf
  • Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. Naci, Huseyin; Guan, Xiaodong; Woloshin, Steven; Xu, Ziyue; Wagner, Anita K. picture_as_pdf
  • Communication of uncertainties about recent cancer drugs in large language models. Cherla, Avi; Naci, Huseyin; Woloshin, Steven; Wagner, Anita Katharina; Ong, Mei-Sing
  • Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer:protocol for a systematic review and network meta-analysis from the CIRCLE group. Athanasiou, Antonios; Veroniki, Areti Angeliki; Efthimiou, Orestis; Kalliala, Ilkka; Naci, Huseyin; Bowden, Sarah; Paraskevaidi, Maria; Martin-Hirsch, Pierre; Bennett, Philip; Paraskevaidis, Evangelos; Salanti, Georgia; Kyrgiou, Maria picture_as_pdf
  • Decision making under uncertainty:comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Vreman, Rick A.; Naci, Huseyin; Goettsch, Wim G.; Mantel-Teeuwisse, Aukje K.; Schneeweiss, Sebastian G.; Leufkens, Hubert G.M.; Kesselheim, Aaron S. picture_as_pdf
  • Effectiveness of interventions for dementia in low- and middle-income countries:protocol for a systematic review, pairwise and network meta-analysis. Salcher-Konrad, Maximilian; Naci, Huseyin; McDaid, David; Alladi, Suvarna; Oliveira, Déborah; Fry, Andra; Hussein, Shereen; Knapp, Martin; Comas-Herrera, Adelina; Musyimi, Christine; Ndetei, David; Lopez-Ortega, Mariana picture_as_pdf
  • Faster UK drug approvals by relying on other countries. Cherla, Avi; Davis, Courtney; Mossialos, Elias; Naci, Huseyin
  • Health Technology Assessment in the US—a word of caution—reply. Wouters, Olivier J.; Naci, Huseyin; Papanicolas, Irene
  • How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. Naci, Huseyin; Salcher-Konrad, Maximilian; Dias, Sofia; Blum, Manuel R.; Sahoo, Samali Anova; Nunan, David; Ioannidis, John P. A. picture_as_pdf
  • NITRATE-CIN Study:Protocol of a Randomized (1:1) Single-Center, UK, Double-Blind Placebo-Controlled Trial Testing the Effect of Inorganic Nitrate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography for Acute Coronary Syndromes. Beirne, Anne Marie; Mitchelmore, Oliver; Palma, Susana; Andiapen, Mervyn; Rathod, Krishnaraj S.; Hammond, Victoria; Bellin, Anna; Cooper, Jackie; Wright, Paul; Antoniou, Sotiris; Yaqoob, Muhammad Magdi; Naci, Huseyin; Mathur, Anthony; Ahluwalia, Amrita; Jones, Daniel A. picture_as_pdf
  • Negotiating drug prices in the US - lessons from Europe. Vokinger, Kerstin N.; Naci, Huseyin picture_as_pdf
  • Patients deserve better information on new drugs. Davis, Courtney; Wagner, Anita K.; Mintzes, Barbara; Scowcroft, Henry; Woloshin, Steven; Naci, Huseyin
  • Planning a future randomized clinical trial based on a network of relevant past trials. Salanti, Georgia; Nikolakopoulou, Adriani; Sutton, Alex J.; Reichenbach, Stephan; Trelle, Sven; Naci, Huseyin; Egger, Matthias
  • Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20:a retrospective analysis. Naci, Huseyin; Murphy, Peter; Woods, Beth; Lomas, James; Wei, Jinru; Papanicolas, Irene picture_as_pdf
  • Preferences for speed of access versus certainty of the survival benefit of new cancer drugs:a discrete choice experiment. Forrest, Robin; Lagarde, Mylene; Aggarwal, Ajay; Naci, Huseyin picture_as_pdf
  • Prevalence, diagnostic delay and economic burden of endometriosis and its impact on quality of life:results from an Eastern Mediterranean population. Swift, Bethan; Taneri, Bahar; Becker, Christian M.; Basarir, Hasan; Naci, Huseyin; Missmer, Stacey A.; Zondervan, Krina T.; Rahmioglu, Nilufer picture_as_pdf
  • Prioritising patients in negotiations over drug pricing. Forrest, Robin; Naci, Huseyin
  • Producing and using timely comparative evidence on drugs:lessons from clinical trials for covid-19. Naci, Huseyin; Kesselheim, Aaron S.; Rttingen, John Arne; Salanti, Georgia; Vandvik, Per O.; Cipriani, Andrea description
  • Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. Dawoud, Dalia; Naci, Huseyin; Ciani, Oriana; Bujkiewicz, Sylwia picture_as_pdf
  • Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. Fu, Mengyuan; Naci, Huseyin; Booth, Christopher M.; Gyawali, Bishal; Cosgrove, Austin; Toh, Sengwee; Xu, Ziyue; Guan, Xiaodong; Ross-Degnan, Dennis; Wagner, Anita K.
  • Recalibrating health technology assessment methods for cell and gene therapies. Angelis, Aris; Naci, Huseyin; Hackshaw, Allan picture_as_pdf
  • Recent trends and potential drivers of non-invasive cardiovascular imaging use in the United States of America and England. Petersen, Steffen E.; Friebel, Rocco; Ferrari, Victor; Han, Yuchi; Aung, Nay; Kenawy, Asmaa; Albert, Timothy S.E.; Naci, Huseyin picture_as_pdf
  • Research evaluating the effectiveness of dementia interventions in low- and middle-income countries:a systematic mapping of 340 randomised controlled trials. Salcher-Konrad, Maximilian; Shi, Cheng; Patel, Disha; McDaid, David; Iveth Astudillo García, Claudia; Bobrow, Kirsten; Choy, Jacky C.P.; Comas-Herrera, Adelina; Fry, Andra; Knapp, Martin; Leung, Dara K.Y.; Lopez-Ortega, Mariana; Lorenz, Klara; Musyimi, Christina; Ndetei, David; Nguyen, Tuan A.; Oliveira, Deborah; Putra, Aditya; Vara, Alisha; Wong, Gloria H.Y.; Naci, Huseyin picture_as_pdf
  • Road traffic injury prevention: an assessment of risk exposure and intervention cost-effectiveness in different world regions. Chisholm, Dan; Naci, Huseyin
  • Safeguarding NICE from patient groups' conflicts of interest. Parvanova, Iva; Gentilini, Arianna; Cushing, Jonathan; Naci, Huseyin
  • Specialty drugs:a distinctly American phenomenon. Naci, Huseyin; Kesselheim, Aaron S. picture_as_pdf
  • Strength of evidence supporting cancer drug approvals in China, 2017-2021. Zhang, Yichen; Chen, Dingyi; Fu, Mengyuan; Shi, Luwen; Naci, Huseyin; Wagner, Anita Katharina; Ross, Joseph S.; Guan, Xiaodong
  • Treatment methods for cervical intraepithelial neoplasia in England:a cost‐effectiveness analysis. Tinelli, Michela; Athanasiou, Antonios; Veroniki, Areti angeliki; Efthimiou, Orestis; Kalliala, Ilkka; Bowden, Sarah; Paraskevaidi, Maria; Lyons, Deirdre; Martin‐hirsch, Pierre; Bennett, Phillip; Paraskevaidis, Evangelos; Salanti, Georgia; Kyrgiou, Maria; Naci, Huseyin picture_as_pdf
  • Unintended consequences of coverage laws targeting cancer drugs. Salcher-Konrad, Maximilian; Naci, Huseyin picture_as_pdf
  • Use of adherence monitoring in drug contracts tied to outcomes:put patients first. Bartholomew, Theodore; Naci, Huseyin; Robertson, Emma; Schmidt, Harald picture_as_pdf
  • Why pharmaceutical pricing needs reform. Naci, Huseyin; Woods, Beth; Lomas, James; Wei, Jinru picture_as_pdf
  • The coverage in England of US-approved cancer drugs reply:in reply. Cherla, Avi; Naci, Huseyin; Mossialos, Elias
  • A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. Anderson, Michael; Naci, Huseyin; Morrison, Deborah; Osipenko, Leeza; Mossialos, Elias